Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02941965
Other study ID # IPMCH2016001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 18, 2017
Est. completion date June 30, 2023

Study information

Verified date June 2022
Source International Peace Maternity and Child Health Hospital
Contact He-Feng Huang, MD
Phone +86-21-18017310186
Email hefenghuang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a prospective, randomized (1:1 ratio) clinical trial for patients with severe male-factor infertility with or without preimplantation genetic screening (PGS). Qualified 450 patients are randomized into either of two groups: group A will undergo intracytoplasmic sperm injection (ICSI) without PGS (225 cases), Group B will undergo ICSI with PGS (225 cases). The partners of all participants will receive the same protocol for ovarian stimulation and standardized luteal phase support. The target population will be patients with severe male-factor infertility aged between 20 and 55 years, diagnosed by the ESHER Criteria (Non-obstructive oligospermia,asthenspermia). Women with other reasons of infertility (eg. advanced age, anovulation, endometriosis, and premature ovarian failure) are excluded. The randomization will take place 3-6 days after the oocyte pick-up day by a computer randomization system. The pregnancy test results, pregnancy complications, congenital anomalies, neonatal complications will be followed up by checking medical records and telephone calls.


Recruitment information / eligibility

Status Recruiting
Enrollment 450
Est. completion date June 30, 2023
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 55 Years
Eligibility Inclusion criteria 1. Male partner age of 20-55 years old, Chinese. 2. Male partner has severe male infertility (defined as a semen concentrate less than 5×10^6/ml, and/or with a progressive motility less than 10%). 3. Proposed ICSI to assist pregnancy. 4. Fully explain the nature of the research and obtain the informed consent of the subject before carrying out any procedure in the research protocol. If a subject is not capable of expressing opinions, the legal representative of the subject can sign the informed consent on behalf of the subject. Exclusion criteria Any one of the following criteria should be excluded from this study: 1. Male partner had been diagnosed with obstructive azoospermia, sexual dysfunction, and immune infertility. 2. Female partner at 38 years of ages and older. 3. Female partner has uterine abnormalities such as uterine malformations (unicornuate uterus, mediastinal uterus, double uterus, double horn uterus, etc.), adenomyosis, submucosal fibroids or intrauterine adhesions. 4. Female partner has a history of recurrent abortion, including biochemical pregnancy (=3 time miscarriages). 5. One of the couples has abnormal chromosomal karyotypes, excluding chromosomal polymorphisms. 6. Female partner has contraindications for assisted reproduction, such as poorly controlled type I or type II diabetes mellitus; undiagnosed liver disease or abnormal liver function (abnormal serum liver enzymes); kidney disease or abnormal kidney function; severe anemia; history of deep venous thrombosis; history of pulmonary embolism; history of cerebrovascular accident; poorly controlled hypertension or diagnosed heart disease; history of cervical cancer, endometrial cancer or breast cancer; unexplained vaginal bleeding. 7. Male partner has contraindications for assisted reproduction, such as poorly controlled type I or type II diabetes mellitus; undiagnosed liver disease or abnormal liver function (abnormal serum liver enzymes); kidney disease or abnormal kidney function; severe anemia; history of deep venous thrombosis; history of pulmonary embolism; history of cerebrovascular accident; poorly controlled hypertension or diagnosed heart disease. 8. One of the couple refuses to cooperate with the study. 9. Patients who have been included in the experimental group or control group of this study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ICSI without PGS
Selection of embryos are based on morphology criteria on the 5th day of ICSI.
ICSI with PGS
PGS will be applied to selected embryos on the 5th day of ICSI.

Locations

Country Name City State
China International Peace Maternity & Child Health Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
International Peace Maternity and Child Health Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary live birth rate This will be based on the outcome of either the PGS+ICSI or the outcome of the ICSI after first embryo transfer cycle. 42 weeks
Secondary clinical pregnancy rate Clinical pregnancy was defined as an observation of gestational sac via ultrasonography. 35 days after embryo transfer
Secondary implantation rate Implantation rate was defined as the percentage of fetal heart beat among total transferred embryos at 12 weeks' gestational age. 11-12 weeks after embryo transfer
Secondary biochemical pregnancy rate Biochemical pregnancy was defined as numbers of women with an elevated serum ß-hCG level of more than 10 mIU/ml. 2 weeks after embryo transfer
Secondary pregnancy loss rate Pregnancy loss is defined as any reason that resulted in failure of an embryo to develop, embryonic or fetal death, or spontaneous expulsion of a pregnancy. 28 gestational weeks in maximum
Secondary ectopic pregnancy rate Ectopic pregnancy is defined as an embryo implanted outside the uterine. 12 gestational weeks in maximum
Secondary Congenital Anomalies rate Congenital anomaly included deformity and development abnormality of any organs or systems. 1 day after delivery
Secondary neonatal complication rate Neonatal complication includes neonatal respiratory disorders, neonatal cerebral palsy, neonatal encephalopathy and other disease that should been sent into neonatal ICU. 1 day after delivery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Recruiting NCT04955782 - Abstinence Period and Semen Quality
Recruiting NCT05506722 - Using of Testes Shocker in Improving the Spermatogenesis and Sperms Activity N/A
Not yet recruiting NCT03988361 - Selection of Non Apoptotic Human Sperm for in Vitro Fertilization by Using Magnetic Activated Cell Sorting (MACS)
Completed NCT03319654 - Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle N/A
Not yet recruiting NCT05597631 - G-IVF and Sperm Parameters N/A
Completed NCT05919186 - Effects of Antioxidant Supplementation of Culture Media on IVF Embryos N/A
Recruiting NCT03588949 - Role of Nutritional Support in Idiopathic Male Infertility N/A
Recruiting NCT03527043 - Impact of Escitalopram on Sperm DNA Fragmentation Phase 2
Completed NCT02932865 - Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility
Completed NCT02310087 - Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures N/A
Completed NCT00385346 - Expressive Writing in Male Infertility N/A
Completed NCT04509583 - The Role of Micro Nutrient Supplement in Improvement of the Sperm DNA Fragmentation N/A
Recruiting NCT04144244 - Comparison of the Effect of Microchip and Density Gradient Methods in Intrauterine Insemination Cycles N/A
Recruiting NCT04452305 - Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting N/A
Completed NCT05461079 - Sperm Phenotype and Differentially Methylated Regions
Recruiting NCT05205733 - Expanding Fertility Care to Poor and Low Resourced Settings Study N/A
Completed NCT03960229 - The Evaluation of the Effect of Microfluidic Sperm Sorting Chip 'Labs-on-a-chip' on IVF Success in Male Factor N/A
Not yet recruiting NCT06050031 - Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility
Not yet recruiting NCT03090438 - IVF Outcomes After Varicocele Repair N/A